РОЛЬ ИНТРАТУМОРАЛЬНЫХ ДЕНДРИТНЫХ КЛЕТОК В ПРОГРЕССИРОВАНИИ ПЛОСКОКЛЕТОЧНЫХ КАРЦИНОМ

Цель исследования – обобщить данные о роли опухоль-ассоциированных дендритных клеток (ДК) в формировании микроокружения плоскоклеточных карцином, их участии в развитии иммуновоспалительных реакций в строме опухоли и связи с различными формами прогрессирования опухолевой болезни.

Материал и методы. Поиск соответствующих источников производился в международных системах Pubmed, Google Scholar, Elibrary с января 2000 г. по декабрь 2017 г. В обзор включены 79 публикаций по исследуемой теме.

Результаты. В обзоре дана основная характеристика разных типов ДК, включая клетки Лангерганса (КЛ). Описаны различные современные методы идентификации данных клеток. Проанализирована информация о ДК в плоскоклеточных карциномах различных локализаций, о влиянии опухоли на функции ДК, о связи количества ДК и их функциональных характеристик с инвазивными и метастатическими потенциями опухоли, безрецидивной, безметастатической и общей выживаемостью. Проанализирована информация о связи ДК в плоскоклеточных карциномах различных локализаций с эффективностью химиотерапии, лучевой терапии и химиолучевой терапии. Проанализирована связь между количественными и качественными характеристиками ДК и особенностями развития иммуновоспалительных реакций в микроокружении опухоли.

Заключение. Методики выявления ДК разнообразны, однако чувствительность каждой из них, как и сопоставление разных методов оценки количества и функциональных характеристик ДК, плохо изучены. Практически отсутствуют данные о связи длины отростков ДК с параметрами инвазивности и метастатической потенции опухоли, безрецидивной, безметастатической и общей выживаемости. Представлены результаты, свидетельствующие об имеющейся связи количества ДК с проявлениями опухолевого прогрессирования, однако эти данные противоречивы. Данных относительно связи функционального состояния и количества ДК с гематогенным метастазированием плоскоклеточных карцином в исследованной литературе практически нет. Недостаточно изучена и связь опухоль-ассоциированных ДК с типами иммуновоспалительных реакций в строме опухолей. 

1. Lasisi T.J., Oluwasola A.O., Lasisi O.A., Akang E.E. Association between langerhans cells population and histological grade of oral squamous cell carcinoma. J Oral Maxillofac Pathol. 2013 Sep; 17(3): 329–33. doi: 10.4103/0973-029X.125177.

2. Jaitley S., Saraswathi T. Pathophysiology of Langerhans cells. J Oral Maxillofac Pathol. 2012 May; 16(2): 239–44. doi: 10.4103/0973-029X.99077.

3. Cutler C.W., Jotwani R. Dendritic cells at the oral mucosal interface. J Dent Res. 2006; 85: 678–89. doi: 10.1177/154405910608500801.

4. Ma Y., Shurin G.V., Gutkin D.W., Shurin M.R. Tumor associated regulatory dendritic cells. Semin Cancer Biol. 2012 Aug; 22(4): 298–306. doi: 10.1016/j.semcancer.2012.02.010.

5. Steinman R.M. The dendritic cell system and its role in immunogenicity. Annu Rev Immunol. 1991; 9: 271–96. doi: 10.1146/annurev.iy.09.040191.001415.

6. Ginhoux F., Tacke F., Angeli V., Bogunovic M., Loubeau M., Dai X-M., Stanley E.R., Randolph G.J., Merad M. Langerhans cells arise from monocytes in vivo. Nature Immunology 2006; 7: 265–273. doi:10.1038/ni1307.

7. Schuler G., Steinman R.M. Murine epidermal Langerhans cells mature into potent immunostimulatory dendritic cells in vitro. J Exp Med 1985; 161: 526–546. doi: 10.1084/jem.161.3.526.

8. Stoitzner P. The Langerhans cell controversy: are they immunostimulatory or immunoregulatory cells of the skin immune system? Immunol Cell Biol. 2010 May-Jun; 88(4): 348–50. doi: 10.1038/icb.2010.46.

9. Rani S.V., Aravindha B., Leena S., Balachander N., Malathi L.K., Masthan M.K. Role of abnormal Langerhans cells in oral epithelial dysplasia and oral squamous cell carcinoma: A pilot study. J Nat Sci Biol Med. 2015 Aug; 6(Suppl 1): S128–33. doi: 10.4103/0976-9668.166120.

10. de Witte L., Nabatov A., Pion M., Fluitsma D., de Jong M.A., de Gruijl T., Piguet V., van Kooyk Y., Geijtenbeek T.B. Langerin is a natural barrier to HIV-1 transmission by Langerhans cells. Nature Med. 2007; 13(3): 367–71. doi: 10.1038/nm1541.

11. Ten Kate A.R. Oral Histology. Development, structure and Function. 5th edition. Missouri: Mosby Year Book Inc, 1996. 497.

12. Lombardi T., Hauser C., Budtz-Jörgensen E. Langerhans cells: structure, function and role in oral pathological conditions. J Oral Pathol Med. 1993 May; 22(5): 193–202.

13. Upadhyay J., Upadhyay R.B., Agrawal P., Jaitley S., Shekhar R. Langerhans cells and their role in oral mucosal diseases. N Am J Med Sci. 2013 Sep; 5(9): 505–14. doi: 10.4103/1947-2714.118923.

14. Teunissen M.B. Dynamic nature and function of epidermal Langerhans cells in vivo and in vitro: a review, with emphasis on human Langerhans cells. Histochem J. 1992 Oct; 24(10): 697–716.

15. Barrett A.W., Cruchley A.T., Williams D.M. Oral mucosal Langerhans’ cells. Crit Rev Oral Biol Med. 1996; 7: 36–58.

16. Chomiczewska D., Trznadel-Budźko E., Kaczorowska A., Rotsztejn H. The role of Langerhans cells in the skin immune system. Pol Merkur Lekarski. 2009 Mar; 26(153): 173–7.

17. Teunissen M.B. Dynamic nature and function of epidermal Langerhans cells in vivo and in vitro: a review, with emphasis on human Langerhans cells. Histochem J. 1992 Oct; 24(10): 697–716.

18. Furio L., Briotet I., Journeaux A., Billard H., Péguet-Navarro J. Human Langerhans cells are more efficient than CD14(-) CD1c(+) dermal dendritic cells at priming naive CD4(+) T cells. J Invest Dermatol. 2010 May; 130(5): 1345–54. doi: 10.1038/jid.2009.424.

19. Kaplan D.H. In vivo function of Langerhans cells and dermal dendritic cells. Trends Immunol. 2010 Dec; 31(12): 446–51. doi: 10.1016/j.it.2010.08.006.

20. Hogan A.D., Burks A.W. Epidermal Langerhans’ cells and their function in the skin immune system. Ann Allergy Asthma Immunol. 1995 Jul; 75(1): 5–10.

21. Lutz M.B., Schuler G. Immature, semi-mature and fully mature dendritic cells: which signals induce tolerance or immunity? Trends Immunol. 2002; 23: 445–449.

22. Menges M., Rossner S., Voigtlander C., Schindler H., Kukutsch N.A., Bogdan C., Erb K., Schuler G., Lutz M.B. Repetitive injections of dendritic cells matured with tumor necrosis factor alpha induce antigen-specific protection of mice from autoimmunity. J Exp Med. 2002 Jan 7; 195(1): 15–21. doi: 10.1084/jem.20011341.

23. Costa N.L., Gonçalves A.S., Martins A.F., Arantes D.A., Silva T.A., Batista A.C. Characterization of dendritic cells in lip and oral cavity squamous cell carcinoma. J Oral Pathol Med. 2016; 45(6): 418–24. doi: 10.1111/jop.12380.

24. Maloth A., Dorankula S.P.R., Pasupula A.P., Thokala M.R., Muddana K., Ramavath R. A Comparative immunohistochemical analysis of Langerhans cells in oral mucosa, oral lichen planus and oral squamous cell carcinoma. J Clin Diagn Res. 2015 Jul; 9(7): ZC76–9. doi: 10.7860/JCDR/2015/14170.6235.

25. Reichert T.E., Scheuer C., Day R., Wagner W., Whiteside T.L. The number of intratumoral dendritic cells and zeta-chain expression in T cells as prognostic and survival biomarkers in patients with oral carcinoma. Cancer. 2001; 91: 2136–47.

26. Shurin M., Salter R. Dendritic Cells in Cancer. New York: Springer; 2009. 396. doi: 10.1007/978-0-387-88611-4.

27. Rao N.N., Upadhyay J., Upadhyay R.B. A comparative analysis of langerhans cell in oral epithelial dysplasia and oral squamous cell carcinoma using antibody CD-1a. J Cancer Res Ther. 2012 Oct-Dec; 8(4): 591–7. doi: 10.4103/0973-1482.106565.

28. Diaconescu D.E., Dima L., Marinescu D.M., Ţânţu M.M., Rogozea L.M. S100-positive dendritic cells in squamous cell laryngeal cancer. Rom J Morphol Embryol. 2014; 55(4): 1371–5.

29. Kikuchi K., Kusama K., Taguchi K., Ishikawa F., Okamoto M., Shimada J., Sakashita H., Yamamo Y. Dendritic cells in human squamous cell carcinoma of the oral cavity. Anticancer Res. 2002 Mar-Apr; 22(2A): 545–57.

30. Yilmaz T., Gedikoglu G., Çelik A., Önerci M., Turan E. Prognostic significance of Langerhans cell infiltration in cancer of the larynx. Otolaryngol Head Neck Surg. 2005 Feb; 132(2): 309–16.

31. Ikeguchi M., Ikeda M., Tatebe S., Maeta M., Kaibara N. Clinical significance of dendritic cell infiltration in esophageal squamous cell carcinoma. OncolRep. 1998 Sep-Oct; 5(5): 1185–9. doi: 10.1016/j. otohns.2004.04.018.

32. Esteban F., Ruiz-Cabello F., Gonzalez-Moles M.A., Lopez-Gonzalez M.A., Funez R., Redondo M. Clinical Significance of Langerhans Cells in Squamous Cell Carcinoma of the Larynx. J Oncol. 2012; 2012: 753296. doi: 10.1155/2012/753296.

33. Schröder S., Schwarz W., Rehpenning W., Löning T., Böcker W. Dendritic/Langerhans cells and prognosis in patients with papillary thyroid carcinomas. Immunocytochemical study of 106 thyroid neoplasms correlated to follow-up data. Am J Clin Pathol. 1988 Mar; 89(3): 295–300. doi: 10.1093/ajcp/89.3.295.

34. Lissoni P., Vigore L., Ferranti R., Bukovec R., Meregalli S., Mandala M., Barni S., Tancini G., Fumagalli L., Giani L. Circulating dendritic cells in early and advanced cancer patients: diminished percent in the metastatic disease. J. Biol. Regul. Homeost. Agents 1999; 13: 216–219.

35. Ma Y., Shurin G.V., Peiyuan Z., Shurin M.R. Dendritic Cells in the Cancer Microenvironment. J Cancer. 2013; 4(1): 36–44. doi: 10.7150/jca.5046.

36. Yang W., Yu J. Immunologic Function of Dendritic Cells in Esophageal Cancer. Dig Dis Sci. 2008 Jul; 53(7): 1739–46. doi: 10.1007/s10620-007-0095-8.

37. Chen W.K., Chen F.J., Zeng Z.Y., Wu G.H., Guo Z.M., Wei M.W., Yang A.K., Zhang Q., He J.H., Hou J.H. Expression of S100-labeled dendritic cells in glottic squamous cell carcinoma and its correlation to prognosis. Ai Zheng. 2005 Oct; 24(10): 1272–5.

38. Kikuchi K., Kusama K., Sano M., Nakanishi Y., Ishige T., Ohni S., Oinuma T., Nemoto N. Vascular Endothelial Growth Factor And Dendritic Cells In Human Squamous Cell Carcinoma Of The Oral Cavity. Аnticancer Res 2006; 26: 1833–1848.

39. O’Donnell R.K., Mick R., Feldman M., Hino S., Wang Y., Brose M.S., Muschel R.J. Distribution of dendritic cell subtypes in primary oral squamous cell carcinoma is inconsistent with a functional response. Cancer Lett. 2007 September 18; 255(1): 145–152. doi: 10.1016/j.canlet.2007.04.003.

40. Karakök M., Bayazit Y.A., Ucak R., Ozer E., Kanlikama M., Mumbuc S., Sari I. Langerhans cell related inflammatory reaction in laryngeal squamous cell carcinoma. Auris Nasus Larynx. 2003 Feb; 30(1): 81–4.

41. Kim W.S., Kim H., Kwon K.W., Im S.H., Lee B.R., Ha S.J., Shin S.J. Cisplatin induces tolerogenic dendritic cells in response to TLR agonists via the abundant production of IL-10, thereby promoting Th2- and Tr1- biased T-cell immunity. Oncotarget. 2016 Jun 7; 7(23): 33765–82. doi: 10.18632/oncotarget.9260.

42. Di Blasio S., Wortel I., van Bladel D.A.G., de Vries L.E., Duivemande Boer T., Worah K., de Haas N., Buschow S.I., de Vries I.J.M., Figdor C.G., Hato S.V. Human CD1c+ DCs are critical cellular mediators of immune responses induced by immunogenic cell death. Oncoimmunology. 2016 Aug 3; 5(8): e1192739. doi: 10.1080/2162402X.2016.1192739.

43. Shurin M.R., Shurin G.V., Lokshin A., Yurkovetsky Z.R., Gutkin D.W., Chatta G., Zhong H., Han B., Ferris R.L. Intratumoral cytokines/chemokines/growth factors and tumor infiltrating dendritic cells: friends or enemies? Cancer Metastasis Rev. 2006 Sep; 25(3): 333–56.

44. Shurin M.R., Yurkovetsky Z.R., Tourkova I.L., Balkir L., Shurin G.V. Inhibition of CD40 expression and CD40-mediated dendritic cell function by tumor-derived IL-10. Int J Cancer. 2002 Sep 1; 101(1): 61–8. doi: 10.1002/ijc.10576.

45. Tourkova I.L., Shurin G.V., Chatta G.S., Perez L., Finke J., Whiteside T.L., Ferrone S., Shurin M.R. Restoration by IL-15 of MHC class I antigen-processing machinery in human dendritic cells inhibited by tumor-derived gangliosides. J Immunol. 2005; 175: 3045–52. doi: 10.4049/jimmunol.175.5.3045.

46. Tourkova I.L., Shurin G.V., Wei S., Shurin M.R. Small rho GTPases mediate tumor-induced inhibition of endocytic activity of dendritic cells. J Immunol. 2007 Jun 15; 178(12): 7787–93.

47. Makarenkova V.P., Shurin G.V., Tourkova I.L., Balkir L., Pirtskhalaishvili G., Perez L., Gerein V., Siegfried J.M., Shurin M.R. Lung cancerderived bombesin-like peptides down-regulate the generation and function of human dendritic cells. J Neuroimmunol. 2003; 145: 55–67

48. Bennaceur K., Popa I., Portoukalian J., Berthier-Vergnes O., Peguet-Navarro J. Melanoma-derived gangliosides impair migratory and antigen-presenting function of human epidermal Langerhans cells and induce their apoptosis. Int Immunol. 2006; 18: 879–86. doi: 10.1093/intimm/dxl024.

49. Menetrier-Caux C., Montmain G., Dieu M.C., Bain C., Favrot M.C., Caux C., Blay J.Y. Inhibition of the differentiation of dendritic cells from CD34+ progenitors by tumor cells: role of interleukin-6 and macrophage colony-stimulating factor. Blood. 1998; 92(12): 4778–4791.

50. Sombroek C.C., Stam A.G.M., Masterson A.J., Lougheed S.M., Schakel M.J., Meijer C.J., Pinedo H.M., van den Eertwegh A.J., Scheper R.J., de Gruijl T.D. Prostanoids play a major role in the primary tumor-induced inhibition of dendritic cell differentiation. J Immunol. 2002; 168(9): 4333–4343. doi: 10.4049/jimmunol.168.9.4333.

51. Zou W. Immunosuppressive networks in the tumour environment and their therapeutic relevance. Nat Rev Cancer. 2005; 5(4): 263–274. doi: 10.1038/nrc1586.

52. Mahnke K., Schmitt E., Bonifaz L., Enk A.H., Jonuleit H. Immature, but not inactive: the tolerogenic function of immature dendritic cells. Immunol Cell Biol. 2002 Oct; 80(5): 477–83.

53. Levings M.K., Gregori S., Tresoldi E., Cazzaniga S., Bonini C., Roncarolo M.G. Differentiation of Tr1 cells by immature dendritic cells requires IL-10 but not CD25+CD4+ Tr cells. Blood. 2005; 105: 1162–9. doi: 10.1182/blood-2004-03-1211.

54. Dudek A.M., Martin S., Garg A.D., Agostinis P. Immature, SemiMature, and Fully Mature Dendritic Cells: Toward a DC-Cancer Cells Interface That Augments. Front Immunol. 2013 Dec 11; 4: 438. doi: 10.3389/fimmu.2013.00438.

55. Enk A.H., Jonuleit H., Saloga J., Knop J. Dendritic cells as mediators of tumor-induced tolerance in metastatic melanoma. Int J Cancer. 1997; 73: 309–16. doi: 10.1002/(sici)1097-0215(19971104)73:33.0.co;2-3.

56. Munn D.H., Sharma M.D., Lee J.R., Jhaver K.G., Johnson T.S., Keskin D.B., Marshall B., Chandler P., Antonia S.J., Burgess R., Slingluff C.L.Jr., Mellor A.L. Potential regulatory function of human dendritic cells expressing indoleamine 2,3-dioxygenase. Science. 2002; 297: 1867–70. doi: 10.1126/science.1073514.

57. Mellor A.L., Chandler P., Baban B., Hansen A.M., Marshall B., Pihkala J., Waldmann H., Cobbold S., Adams E., Munn D.H. Specific subsets of murine dendritic cells acquire potent T cell regulatory functions following CTLA4-mediated induction of indoleamine 2,3dioxygenase. Int Immunol. 2004 Oct; 16(10): 1391–401.

58. Cuncha A., Michlein M., Murta E. Pattern response of dendritic cells in the tumor microenvironment and breast cancer. World J Clin Oncol. 2014 Aug 10; 5(3): 495–502. doi: 10.5306/wjco.v5.i3.495.

59. Bjorck P., Leong H.X., Engleman E.G. Plasmacytoid dendritic cell dichotomy: identification of IFN-alpha producing cells as a phenotypically and functionally distinct subset. J Immunol. 2011 Feb 1; 186(3): 1477–85. doi: 10.4049/jimmunol.1000454.

60. Reizis B., Colonna M., Trinchieri G., Barrat F., Gilliet M. Plasmacytoid dendritic cells: one-trick ponies or workhorses of the immune system? Nat Rev Immunol. 2011 Jul 22; 11(8): 558–65. doi: 10.1038/nri3027.

61. Vermi W., Soncini M., Melocchi L., Sozzani S., Facchetti F. Plasmacytoid dendritic cells and cancer. J Leukoc Biol. 2011 Oct; 90(4): 681–90. doi: 10.1189/jlb.0411190.

62. Akbari O., De Kruyff R.H., Umetsu D.T. Pulmonary dendritic cells producing IL-10 mediate tolerance induced by respiratory exposure to antigen. Nat Immunol. 2001; 2: 725–31. doi: 10.1038/90667.

63. Watkins S.K., Zhu Z., Riboldi E., Shafer-Weaver K.A., Stagliano K.E., Sklavos M.M., Ambs S., Yagita H., Hurwitz A.A. FOXO3 programs tumor-associated DCs to become tolerogenic in human and murine prostate cancer. J Clin Invest. 2011; 121: 1361–72. doi: 10.1172/JCI44325.

64. Hurwitz A.A., Watkins S.K. Immune suppression in the tumor microenvironment: a role for dendritic cell-mediated tolerization of T cells. Cancer Immunol Immunother. 2012 Feb; 61(2): 289–293. doi: 10.1007/s00262-011-1181-5.

65. Krempski J., Karyampudi L., Behrens M.D., Erskine C.L., Hartmann L., Dong H., Goode E.L., Kalli K.R., Knutson K.L. Tumor-infiltrating programmed death receptor-1+ dendritic cells mediate immune suppression in ovarian cancer. J Immunol. 2011 Jun 15; 186(12): 6905–13. doi: 10.4049/jimmunol.1100274.

66. Grohmann U., Fallarino F., Puccetti P. Tolerance, DCs and tryptophan: much ado about IDO. Trends Immunol. 2003 May; 24(5): 242–8.

67. Kusume A., Sasahira T., Luo Y., Isobe M., Nakagawa N., Tatsumoto N., Fujii K., Ohmori H., Kuniyasu H. Suppression of dendritic cells by HMGB1 is associated with lymph node metastasis of human colon cancer. Pathobiology. 2009; 76(4): 155–62. doi: 10.1159/000218331.

68. Esche C., Lokshin A., Shurin G.V., Gastman B.R., Rabinowich H., Watkins S.C., Lotze M.T., Shurin M.R. Tumor’s other immune targets: dendritic cells. J Leukoc Biol. 1999; 66: 336–44. doi: 10.1002/jlb.66.2.336.

69. Zou W. Immunosuppressive networks in the tumour environment and their effect in dendritic cells. Nat Rev Cancer. 2005 Apr; 5(4): 263–74. doi: 10.1038/nrc1586.

70. Kiertscher S.M., Luo J., Dubinett S.M., Roth M.D. Tumors promote altered maturation and early apoptosis of monocyte-derived dendritic cells. J Immunol. 2000; 164: 1269–76. doi: 10.4049/jimmunol.164.3.1269.

71. Onishi H., Morisaki T., Baba E., Kuga H., Kuroki H., Matsumoto K., Tanaka M., Katano M. Dysfunctional and short-lived subsets in monocyte-derived dendritic cells from patients with advanced cancer. Clin Immunol. 2002; 105: 286–95.

72. Dieu-Nosjean M.C., Antoine M., Danel C., Heudes D., Wislez M., Poulot V., Rabbe N., Laurans L., Tartour E., de Chaisemartin L., Lebecque S., Fridman W.H., Cadranel J. Long-term survival for patients with non-small-cell lung cancer with intratumoral lymphoid structures. J Clin Oncol. 2008 Sep 20; 26(27): 4410–7. doi: 10.1200/JCO.2007.15.0284.

73. Gallo O., Libonati G.A., Gallina E., Fini-Storchi O., Giannini A., Urso C., Bondi R. Langerhans cells related to prognosis in patients with laryngeal carcinoma. Arch Otolaryngol Head Neck Surg. 1991 Sep; 117(9): 1007–10.

74. Karpathiou G., Casteillo F., Giroult J.B., Forest F., Fournel P., Monaya A, Froudarakis M, Dumollard J.M., Prades J.M., Peoc’h M. Prognostic impact of immune microenvironment in laryngeal and pharyngeal squamous cell carcinoma: Immune cell subtypes, immuno-suppressive pathways and clinicopathologic characteristics. Oncotarget. 2017 Mar 21; 8(12): 19310–19322. doi: 10.18632/oncotarget.14242.

75. Brandwein-Gensler M., Teixeira M.S., Lewis C.M., Lee B., Rolnitzky L., Hille J.J., Genden E., Urken M.L., Wang B.Y. Oral Squamous Cell Carcinoma: Histologic Risk Assessment, but Not Margin Status, Is Strongly Predictive of Local Disease-free and Overall Survival. Am J Surg Pathol 2005; 29: 167–178.

76. Таширева Л.А., Перельмутер В.М., Манских В.Н., Денисов Е.В., Савельева О.Е., Кайгородова Е.В., Завьялова М.В. Типы иммуновоспалительных реакций как алгоритмы взаимодействия клеток в условиях репаративной регенерации и опухолевого роста. Биохимия. 2017; 82(5): 732–748.

77. Rissoan M.C., Soumelis V., Kadowaki N., Grouard G., Briere F., de Waal Malefyt R., Liu Y.J. Reciprocal control of T helper cell and dendritic cell differentiation. Science. 1999; 283: 1183–1186. doi: 10.1126/science.283.5405.1183.

78. Vieira P.L., de Jong E.C., Wierenga E.A., Kapsenberg M.L., Kalinski P. Development of Th1-inducing capacity in myeloid dendritic cells requires environmental instruction. J Immunol. 2000; 164: 4507–4512. doi: 10.4049/jimmunol.164.9.4507.

79. Labeur M.S., Roters B., Pers B., Mehling A., Luger T.A., Schwarz T., Grabbe S. Generation of tumor immunity by bone marrow-derived dendritic cells correlates with dendritic cell maturation stage. J Immunol. 1999; 162: 168–175.